Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer
Authors
Keywords
-
Journal
Scientific Reports
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-11
DOI
10.1038/s41598-020-79909-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Detection of Colorectal Cancer and Advanced Adenoma by Liquid Biopsy (Decalib Study): The ddPCR Challenge
- (2020) Audelaure Junca et al. Cancers
- Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer
- (2019) Vincent P Groot et al. CLINICAL CANCER RESEARCH
- Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
- (2019) Thomas Reinert et al. JAMA Oncology
- Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer
- (2019) B Lee et al. ANNALS OF ONCOLOGY
- Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer
- (2019) Isaac Garcia-Murillas et al. JAMA Oncology
- Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
- (2019) Jeanne Tie et al. JAMA Oncology
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- (2018) Axel Grothey et al. NEW ENGLAND JOURNAL OF MEDICINE
- KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
- (2018) Francesco Sclafani et al. Scientific Reports
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing
- (2018) Christina Demuth et al. Translational Oncology
- Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity
- (2018) Ni Ni Moe Myint et al. Cell Death & Disease
- Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
- (2016) Julien Taieb et al. JNCI-Journal of the National Cancer Institute
- Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases
- (2016) Nick Beije et al. Molecular Oncology
- Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
- (2016) Jeanne Tie et al. Science Translational Medicine
- Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
- (2016) Julien Taieb et al. JNCI-Journal of the National Cancer Institute
- Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials
- (2015) D. G. Haller et al. ANNALS OF ONCOLOGY
- Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study
- (2014) M-C Etienne-Grimaldi et al. BRITISH JOURNAL OF CANCER
- KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF-Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)
- (2014) H. H. Yoon et al. CLINICAL CANCER RESEARCH
- Liquid Biopsies: Genotyping Circulating Tumor DNA
- (2014) Luis A. Diaz et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
- (2014) Alain R Thierry et al. NATURE MEDICINE
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
- (2012) H. J. Schmoll et al. ANNALS OF ONCOLOGY
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
- (2011) Daniel G. Haller et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now